Inhaled drug shows promise for rare lung disease combination

AI Summary

The inhaled investigational drug mosliciguat is advancing in clinical trials for treating pulmonary hypertension associated with interstitial lung disease. Phase 2 results demonstrate significant and consistent effects in this rare lung condition, underpinning decades of pulmonary vascular research.

A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced marked and consistent effects in a randomized phase 2 study involving patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), one of the most challenging forms of pulmonary vascular disease.